ARTIVA BIOTHERAPEUTICS INC

Company Overview

Artiva Bio (ARTV) is a clinical-stage biotechnology company developing allogeneic, off-the-shelf natural killer (NK) cell therapies—most notably AlloNK—for B‑cell driven autoimmune diseases and B‑cell malignancies. The company emphasizes in‑house and partner-enabled manufacturing (San Diego cGMP center plus GC Cell capacity in Korea), a cord‑blood based expansion platform, and claims a low projected COGS ($3k–$12k per patient) versus autologous CAR‑T. Artiva is pre‑commercial and pre‑revenue, with materially negative results driven by R&D spend and the 2024 loss of Merck collaboration revenue; management reported cash and investments of $142.4M at June 30, 2025 and a runway into roughly Q2 2027 under current plans.

Executive Compensation Practices

Compensation is likely equity‑heavy and milestone‑oriented, reflecting a pre‑revenue biotech profile where stock‑based awards (options/RSUs) and long‑term incentives align executives to clinical and partnering milestones. Recent filings highlight large non‑cash stock‑based compensation and the conversion of SAFEs at IPO, so equity dilution and valuation assumptions materially affect reported compensation expenses and executive pay decisions. Pay metrics for Artiva executives will plausibly emphasize clinical progress (Phase 1/2 readouts, IND/BLA progress), manufacturing scale‑up/cost control (to realize AlloNK COGS advantages), and securing partnerships or reimbursement pathways given the company’s reliance on collaborators (GC Cell, Affimed) and milestone/licensing obligations. Because G&A has risen post‑IPO to support public‑company operations, compensation plans may also include retention awards for key scientific and manufacturing personnel (many with M.D./Ph.D./Pharm.D. credentials) to protect operational continuity.

Insider Trading Considerations

Insider trading patterns at Artiva should be viewed through the lens of high event risk and informational sensitivity: clinical data releases (B‑NHL, SLE/LN, autoimmune basket trials), partnership updates, and manufacturing/supply‑chain developments are likely material and capable of producing sharp stock moves. Typical biotech protections apply—formal trading windows, blackout periods around clinical readouts, and common use of Rule 10b5‑1 plans—especially given the company’s dependence on third‑party manufacturing and contract milestones that could materially affect valuation. Post‑IPO equity holdings and significant stock‑based compensation create incentives for insiders to diversify over time, so look for staged, rule‑compliant sales after lock‑up expirations and around financing events; conversely, insider purchases are rarer but may signal conviction ahead of clinical inflection points. Regulators and investors will also scrutinize trades tied to partner negotiations or milestone payments to GC Cell, as those arrangements can be material non‑public information.